Inhibitor Therapeutics Inc INTI Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.08 unchanged at close Nov 6
Last close · Previous close $0.08
- Market cap
- $29.69MAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$0.08down $0.02, 19.39%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.08Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume9.97KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.04 to $0.12; now $0.08
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
INTI beat the S&P 500 in 3 of 7 periods.
| Period | INTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INTI: down 19.4% S&P 500: down 5.6% | INTI trailed the S&P 500 by 13.8 percentage points Trailed |
| 3M | INTI: down 3.0% S&P 500: down 4.1% | INTI beat the S&P 500 by 1.1 percentage points Beat |
| YTD | INTI: up 75.6% S&P 500: up 8.7% | INTI beat the S&P 500 by 66.9 percentage points Beat |
| 1Y | INTI: up 58.0% S&P 500: up 10.9% | INTI beat the S&P 500 by 47.1 percentage points Beat |
| Long term | ||
| 3Y | INTI: down 21.0% S&P 500: up 75.0% −7.6% vs +20.5% a year | INTI trailed the S&P 500 by 96.0 percentage points Trailed |
| 5Y | INTI: down 53.5% S&P 500: up 67.8% −14.2% vs +10.9% a year | INTI trailed the S&P 500 by 121.3 percentage points Trailed |
| 10Y | INTI: down 81.2% S&P 500: up 313.1% −15.4% vs +15.2% a year | INTI trailed the S&P 500 by 394.3 percentage points Trailed |
$10,000 invested in INTI 10 years ago (Nov 4, 2016) would be worth about $1,881 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
INTI beat the S&P 500 in 3 of 7 periods.
| Period | INTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | INTI: down 19.4% S&P 500: down 5.6% | INTI trailed the S&P 500 by 13.8 percentage points Trailed |
| 3M | INTI: down 3.0% S&P 500: down 4.3% | INTI beat the S&P 500 by 1.3 percentage points Beat |
| YTD | INTI: up 75.6% S&P 500: up 7.8% | INTI beat the S&P 500 by 67.8 percentage points Beat |
| 1Y | INTI: up 58.0% S&P 500: up 9.7% | INTI beat the S&P 500 by 48.3 percentage points Beat |
| Long term | ||
| 3Y | INTI: down 21.0% S&P 500: up 68.8% −7.6% vs +19.1% a year | INTI trailed the S&P 500 by 89.8 percentage points Trailed |
| 5Y | INTI: down 53.5% S&P 500: up 56.9% −14.2% vs +9.4% a year | INTI trailed the S&P 500 by 110.4 percentage points Trailed |
| 10Y | INTI: down 81.2% S&P 500: up 252.6% −15.4% vs +13.4% a year | INTI trailed the S&P 500 by 333.8 percentage points Trailed |
$10,000 invested in INTI 10 years ago (Nov 4, 2016) would be worth about $1,881 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$0.65
Closing high on . Now 87.9% below that record.
Split-adjusted daily closes since Aug 19, 2013.
Stock splits
INTI hasn’t split since its price history begins in 2013.
Valuation
The Nov 6 close compared with reported results. 12-month figures aren’t available until four quarters are reported. Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not available
12-month figures aren’t available until four quarters are reported.
Other valuation measures
- $29.83MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2021 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own INTI DCF in Excel. Value Inhibitor Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY21, the quarter ended Jun 30, 2021, and balance-sheet figures are as of Jun 30, 2021. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY20 (Dec 31, 2020) | $0.00 | −$55.85K | $0.00 |
| Q1 FY21 (Mar 31, 2021) | $0.00 | −$127.84K | $0.00 |
| Q2 FY21 (Jun 30, 2021) | $0.00 | −$66.18K | $0.00 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$1.06M | $0.00 |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $93.72KAs of Jun 30, 2021
Cash plus short- and long-term marketable securities on the Jun 30, 2021 balance sheet.
- Total debt$231.00KAs of Jun 30, 2021
- Net debt$137.28KAs of Jun 30, 2021
- 0.23As of Jun 30, 2021
Current assets divided by current liabilities on the Jun 30, 2021 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Inhibitor Therapeutics Inc
SUBA-Itraconazole (which stands for "super bioavailability") is a patented formulation of itraconazole designed to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole has improved absorption and significantly reduced variability compared to generic Itraconazole, providing patients and prescribers with reduced intra- and inter-patient variability, enabling a more predictable clinical dose response and a reduction in the active drug quantity required to deliver therapeutic levels into the bloodstream. SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for HedgePath's use in clinical trials. An affiliate of Mayne Pharma is HedgePath's majority stockholder and the licensor of the SUBA-Itraconazole technology. About HedgePath Pharmaceuticals HedgePath Pharmaceuticals, Inc. is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath Pharmaceuticals, Inc. is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath is the exclusive U.S. licensee of SUBA-Itraconazole in certain fields. Clinical studies have shown SUBA-Itraconazole to have greater bioavailability than generic itraconazole, a drug that has been approved by FDA for the treatment of certain fungal infections. The Hedgehog signaling pathway is a major regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity and cell proliferation. Based on published research, HedgePath believes that inhibiting the Hedgehog pathway could delay or possibly prevent the development and progression of certain cancers, such as prostate cancer, in humans. Leveraging research undertaken by key investigators in the field, HedgePath is exploring the effectiveness of SUBA-Itraconazole as an anti-cancer agent and to pursue its potential commercialization. HedgePath is headquartered in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Florida, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
INTI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
INTI stock FAQ
What is INTI stock’s price today?
Inhibitor Therapeutics (INTI) traded at $0.08 at the close on , unchanged from the previous close of $0.08. Over the past 52 weeks it has traded between $0.04 and $0.12.
If you invested $1,000 in INTI 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in INTI on would be worth about $188 at the close on , a total return of −81.2%. The same $1,000 would be worth $465 if invested five years ago and $1,580 if invested one year ago. Past performance doesn’t predict future returns.
What is Inhibitor Therapeutics’s market cap?
Inhibitor Therapeutics’s market capitalization is about $29.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.08 (how market cap works). Inhibitor Therapeutics reported 375.88M shares outstanding at the end of its latest quarter ().
Does INTI pay a dividend?
Inhibitor Therapeutics hasn’t paid a dividend in the last twelve months.
What is INTI’s 52-week high and low?
Over the past 52 weeks INTI has traded as low as $0.04 and as high as $0.12. At $0.08 at the close on , it is 36.2% below that high and 97.0% above the low.
What is INTI’s all-time high?
INTI’s highest closing price was $0.65 on , adjusted for stock splits. At $0.08 at the close on , it is 87.9% below that record.
Has INTI stock ever split?
No. INTI hasn’t split since its price history begins in 2013.
How has INTI stock performed?
Including dividends and measured to the close on , INTI has returned +75.6% so far this year and +58.0% over the past year, and −53.5% over five years (−14.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Inhibitor Therapeutics in?
Inhibitor Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Florida, USA.
What exchange does INTI trade on?
Inhibitor Therapeutics trades on the PINK under the ticker symbol INTI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.